Clinical Trials Browser

INDUSTRY × Everolimus × Breast × Clear all

NCT07062965 2026-04-16

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Phase 3 Recruiting

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT06428396 2026-03-24

LITESPARK-029

Phase 2 Recruiting

Breast Neoplasms

NCT05573126 2026-03-20

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Phase 1/2 Recruiting

Breast Neoplasms

NCT06105632 2026-02-13

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Phase 2 Active not recruiting

Breast Neoplasms, Recurrence

NCT05306340 2026-01-30

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

Phase 3 Active not recruiting

Breast Neoplasms

NCT03616587 2026-01-28

SERENA-1

Phase 1 Active not recruiting

Breast Neoplasms

NCT02057133 2026-01-26

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

Phase 1 Active not recruiting

Breast Neoplasms

NCT07024173 2026-01-26

A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer

Phase 3 Recruiting

Breast Neoplasms

NCT07002177 2026-01-07

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

Phase 1/2 Recruiting

Breast Neoplasms

NCT05563220 2026-01-06

ELEVATE

Phase 1/2 Recruiting

Breast Neoplasms

NCT03284957 2025-11-24

AMEERA-1

Phase 1/2 Terminated

136 enrolled 60 charts

Breast Neoplasms

NCT05508906 2025-10-22

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

Phase 1 Recruiting

Breast Neoplasms

NCT05501769 2025-09-26

TACTIVE-E

Phase 1 Completed

Breast Neoplasms

NCT06680921 2025-09-22

A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)

Phase 3 Recruiting

Breast Neoplasms

NCT04188548 2025-06-04

EMBER

Phase 1 Active not recruiting

BreastGynecologic

Breast Neoplasms, Endometrial Neoplasms

NCT03659136 2025-02-24

The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread

Phase 2 Completed

103 enrolled 16 charts

Breast Neoplasms

NCT04818632 2024-12-17

AZD9833

Phase 1 Completed

Breast Neoplasms

NCT05293964 2024-11-29

Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer

Phase 1 Active not recruiting

Breast Neoplasms

NCT05065411 2024-02-26

VERU-024

Phase 3 Terminated

Breast Neoplasms

NCT03312738 2024-01-23

BOLERO-5

Phase 2 Completed

159 enrolled 25 charts

Breast Neoplasms

NCT02258451 2023-11-24

Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer

Phase 2 Completed

283 enrolled 22 charts

Breast Neoplasms

NCT01698918 2023-05-03

BOLERO-4

Phase 2 Completed

202 enrolled 19 charts

Breast Neoplasms

NCT05079360 2023-03-24

Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms

NCT02890069 2023-01-11

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Phase 1 Completed

BreastGastrointestinalGenitourinaryThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT02071862 2022-07-20

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Phase 1 Completed

BreastGenitourinaryOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Mesothelioma, Triple Negative Breast Neoplasms

NCT05108740 2021-12-09

MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast Cancer

No longer available

Breast Neoplasms

NCT02732119 2021-05-05

TRINITI-1

Phase 1/2 Completed

104 enrolled 24 charts

Breast Neoplasms

NCT01857193 2021-04-13

Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer

Phase 1 Completed

Breast Neoplasms

NCT01231659 2021-03-26

Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

Phase 2 Completed

72 enrolled 11 charts

Breast Neoplasms

NCT01783444 2021-02-26

BOLERO-6

Phase 2 Completed

309 enrolled 19 charts

Breast Neoplasms, Neoplasm Metastasis

NCT00426530 2020-12-21

Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer

Phase 1 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT01482156 2020-12-21

Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors

Phase 1 Completed

BreastGenitourinary

Breast Neoplasms, Carcinoma, Renal Cell

NCT02077933 2020-12-08

Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors

Phase 1 Completed

BreastGenitourinary

Breast Neoplasms, Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasms

NCT03176238 2020-04-07

EVEREXES

Phase 3 Completed

235 enrolled 11 charts

Breast Neoplasms

NCT01743560 2019-07-18

4EVERUK

Phase 4 Completed

52 enrolled 16 charts

Breast Diseases, Breast Neoplasms, Neoplasms, Skin Diseases

NCT00876395 2018-12-19

BOLERO-1

Phase 3 Completed

719 enrolled 25 charts

Breast Neoplasms, Neoplasm Metastasis

NCT02248571 2017-11-13

IMPROVE

Phase 4 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT00863655 2017-05-02

BOLERO-2

Phase 3 Completed

724 enrolled 20 charts

Breast Neoplasms

NCT01007942 2017-04-05

BOLERO-3

Phase 3 Completed

569 enrolled 16 charts

Breast Neoplasms

NCT01626222 2017-02-23

MACS2096

Phase 3 Completed

Breast Neoplasms

NCT02069093 2017-02-13

Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer

Phase 2 Completed

92 enrolled 9 charts

Advanced Breast Cancer

NCT02023359 2015-12-29

Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast Cancer

Breast Neoplasms

NCT00426556 2015-12-28

Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer

Phase 1 Completed

88 enrolled 10 charts

Breast Neoplasms, Neoplasm Metastasis

NCT00107016 2013-03-04

Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women

Phase 2 Completed

Breast Neoplasms